Suppr超能文献

反对观点:新型冠状病毒肺炎不会导致抗菌药物耐药性患病率上升。

CON: COVID-19 will not result in increased antimicrobial resistance prevalence.

作者信息

Collignon Peter, Beggs John J

机构信息

Australian Capital Territory Pathology, Canberra Hospital, Garran, Australian Capital Territory, Australia.

Medical School, Australian National University, Canberra, Australia.

出版信息

JAC Antimicrob Resist. 2020 Sep;2(3):dlaa051. doi: 10.1093/jacamr/dlaa051. Epub 2020 Jul 17.

Abstract

Antimicrobial resistance (AMR) is affected by many factors, but too much of our focus has been on antimicrobial usage. The major factor that drives resistance rates globally is spread. The COVID-19 pandemic should lead to improved infection prevention and control practices, both in healthcare facilities and the community. COVID-19 will also have ongoing and profound effects on local, national and international travel. All these factors should lead to a decrease in the spread of resistant bacteria. So overall, COVID-19 should lead to a fall in resistance rates seen in many countries. For this debate we show why, overall, COVID-19 will not result in increased AMR prevalence. But globally, changes in AMR rates will not be uniform. In wealthier and developed countries, resistance rates will likely decrease, but in many other countries there are already too many factors associated with poor controls on the spread of bacteria and viruses (e.g. poor water and sanitation, poor public health, corrupt government, inadequate housing, etc.). In these countries, if economies and governance deteriorate further, we might see even more transmission of resistant bacteria.

摘要

抗菌药物耐药性(AMR)受多种因素影响,但我们过多地将重点放在了抗菌药物的使用上。全球推动耐药率上升的主要因素是传播。新冠疫情应促使医疗机构和社区改进感染预防与控制措施。新冠疫情还将对本地、国家和国际旅行产生持续且深远的影响。所有这些因素都应能减少耐药菌的传播。所以总体而言,新冠疫情应会使许多国家的耐药率下降。在本次辩论中,我们将阐述为何总体上新冠疫情不会导致抗菌药物耐药性患病率上升。但在全球范围内,抗菌药物耐药率的变化并不一致。在较富裕和发达的国家,耐药率可能会下降,但在许多其他国家,已经存在太多与细菌和病毒传播控制不力相关的因素(例如水和卫生条件差、公共卫生状况不佳、政府腐败、住房不足等)。在这些国家,如果经济和治理进一步恶化,我们可能会看到耐药菌的传播更加严重。

相似文献

1
CON: COVID-19 will not result in increased antimicrobial resistance prevalence.
JAC Antimicrob Resist. 2020 Sep;2(3):dlaa051. doi: 10.1093/jacamr/dlaa051. Epub 2020 Jul 17.
2
4
PRO: The COVID-19 pandemic will result in increased antimicrobial resistance rates.
JAC Antimicrob Resist. 2020 Sep;2(3):dlaa049. doi: 10.1093/jacamr/dlaa049. Epub 2020 Jul 17.
5
The impact of the COVID-19 pandemic on antimicrobial resistance: a debate.
JAC Antimicrob Resist. 2020 Sep;2(3):dlaa053. doi: 10.1093/jacamr/dlaa053. Epub 2020 Jul 17.
6
Updated research agenda for water, sanitation and antimicrobial resistance.
J Water Health. 2020 Dec;18(6):858-866. doi: 10.2166/wh.2020.033.
7
Differential Drivers of Antimicrobial Resistance across the World.
Acc Chem Res. 2019 Apr 16;52(4):916-924. doi: 10.1021/acs.accounts.8b00643. Epub 2019 Mar 8.
8
9
It is complicated: Potential short- and long-term impact of coronavirus disease 2019 (COVID-19) on antimicrobial resistance-An expert review.
Antimicrob Steward Healthc Epidemiol. 2022 Feb 18;2(1):e27. doi: 10.1017/ash.2022.10. eCollection 2022.

引用本文的文献

2
3
Three-year impact of COVID-19 pandemic on hospitalized twin pregnancies: evaluation of characteristics and changes in antibiotic prescribing.
Front Med (Lausanne). 2025 Jun 18;12:1546013. doi: 10.3389/fmed.2025.1546013. eCollection 2025.
4
Rebound of Antibiotic Use and Respiratory Infections After Resumption of Normalcy From COVID-19 in Hong Kong.
Infect Drug Resist. 2025 Mar 11;18:1325-1337. doi: 10.2147/IDR.S502126. eCollection 2025.
5
COVID-19 restrictions limited interactions of people and resulted in lowered antimicrobial resistance rates.
JAC Antimicrob Resist. 2024 Aug 8;6(4):dlae125. doi: 10.1093/jacamr/dlae125. eCollection 2024 Aug.
6
A scoping review of bacterial resistance among inpatients amidst the COVID-19 pandemic.
J Glob Antimicrob Resist. 2024 Sep;38:49-65. doi: 10.1016/j.jgar.2024.05.010. Epub 2024 May 23.
9
Microbiological profile of multidrug resistant bacteria before and during COVID-19 in CHU Mohammed VI.
Iran J Microbiol. 2023 Dec;15(6):771-778. doi: 10.18502/ijm.v15i6.14138.
10
Antimicrobial prescribing in a secondary care setting during the COVID-19 pandemic.
JAC Antimicrob Resist. 2023 Nov 13;5(6):dlad117. doi: 10.1093/jacamr/dlad117. eCollection 2023 Dec.

本文引用的文献

1
Prevalence and risk factors for carriage of ESBL-producing Enterobacteriaceae in a population of Dutch travellers: A cross-sectional study.
Travel Med Infect Dis. 2020 Jan-Feb;33:101547. doi: 10.1016/j.tmaid.2019.101547. Epub 2019 Dec 17.
4
An environmental cleaning bundle and health-care-associated infections in hospitals (REACH): a multicentre, randomised trial.
Lancet Infect Dis. 2019 Apr;19(4):410-418. doi: 10.1016/S1473-3099(18)30714-X. Epub 2019 Mar 8.
5
One Health-Its Importance in Helping to Better Control Antimicrobial Resistance.
Trop Med Infect Dis. 2019 Jan 29;4(1):22. doi: 10.3390/tropicalmed4010022.
8
Origin, evolution, and global transmission of community-acquired ST8.
Proc Natl Acad Sci U S A. 2017 Dec 5;114(49):E10596-E10604. doi: 10.1073/pnas.1702472114. Epub 2017 Nov 20.
10
The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace.
J Infect Dis. 2017 Feb 15;215(suppl_1):S28-S36. doi: 10.1093/infdis/jiw282.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验